Guardant Health posted a sharp revenue increase in the second quarter, driven by oncology testing volume and screening growth, and pointed to the FDA’s June approval of Guardant360 Liquid CDx as a companion diagnostic for Boehringer Ingelheim’s Hernexeos in HER2-mutant advanced NSCLC. The company also cited updates to colorectal screening guidance and expanded coverage as additional demand catalysts. Separately, Tempus reported growth in its oncology testing business, helping lift quarterly results and leading management to raise 2026 revenue guidance. Tempus attributed momentum to additional FDA approvals tied to its xT CDx platform and the expected ramp of minimal residual disease (MRD) testing following its Personalis acquisition. Together, the updates reinforce that reimbursement-linked clinical adoption and regulatory clearances continue to drive sustained growth for liquid biopsy and MRD-enabled oncology portfolios.